{"id":60427,"date":"2024-12-03T07:05:06","date_gmt":"2024-12-03T06:05:06","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\/"},"modified":"2024-12-03T07:05:06","modified_gmt":"2024-12-03T06:05:06","slug":"innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\/","title":{"rendered":"Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024"},"content":{"rendered":"<div>\n<p>MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/ANKET?src=hash\" target=\"_blank\">#ANKET<\/a>&#8211;Regulatory News:<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20241202835786\/en\/1245155\/4\/INNATEvertnoirDS.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20241202835786\/en\/1245155\/22\/INNATEvertnoirDS.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20241202835786\/en\/1245155\/4\/INNATEvertnoirDS.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20241202835786\/en\/1245155\/21\/INNATEvertnoirDS.jpg\"><\/a><\/p>\n<p>\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201c<b>Innate<\/b>\u201d or the \u201c<b>Company<\/b>\u201d) today announced that abstracts related to lacutamab health-related quality of life and translational data from the TELLOMAK trial and SAR443579, Sanofi-partnered ANKET<sup>\u00ae<\/sup> asset, have been selected for the American Society of hematology (ASH) Annual Meeting.<\/p>\n<p>\n\u201c<i>We are proud of the progress being made across our multiple programs, including our lead proprietary asset lacutamab and the multi-specific NK cell engagers from our ANKET<sup>\u00ae<\/sup> platform,\u201d<\/i> commented <b>Dr. <\/b><b>Sonia Quaratino, Chief Medical Officer of Innate Pharma<\/b>. \u201c<i>We look forward to presenting data supporting the advancement of our programs at the upcoming ASH 2024 as we move closer to our goal of delivering new treatment options for patients with high unmet medical needs<\/i>.\u201d<\/p>\n<p>\n<b>Details of the presentations<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fash.confex.com%2Fash%2F2024%2Fwebprogram%2FPaper200587.html&amp;esheet=54159774&amp;newsitemid=20241202835786&amp;lan=en-US&amp;anchor=Lacutamab+in+Patients+with+Relapsed+and%2For+Refractory+S%26eacute%3Bzary+Syndrome%3A+Translational+Analysis+from+the+TELLOMAK+Phase+2+Trial&amp;index=1&amp;md5=ba331eee6a1e176a5eac1a1decb72781\" rel=\"nofollow\" shape=\"rect\"><b>Lacutamab in Patients with Relapsed and\/or Refractory S\u00e9zary Syndrome: Translational Analysis from the TELLOMAK Phase 2 Trial<\/b><\/a><br \/>Abstract Number: 1609<br \/>\n<br \/>Presentation Type: Poster Presentation<br \/>\n<br \/>Session: 622. Lymphomas: Translational &#8211; Non-Genetic: Poster I<br \/>\n<br \/>Date and Time: Saturday, Dec. 7, 2024, 5:30 PM \u2013 7:30 PM PT<br \/>\n<\/li>\n<li>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fash.confex.com%2Fash%2F2024%2Fwebprogram%2FPaper194796.html&amp;esheet=54159774&amp;newsitemid=20241202835786&amp;lan=en-US&amp;anchor=Health-Related+Quality+of+Life+in+Patients+with+Relapsed%2FRefractory+Cutaneous+T-Cell+Lymphoma+Treated+By+Lacutamab%3A+Patient-Reported+Outcomes+from+the+Phase+2+TELLOMAK+Trial&amp;index=2&amp;md5=507a4d3b1589e01f0112b6f3e30709a3\" rel=\"nofollow\" shape=\"rect\"><b>Health-Related Quality of Life in Patients with Relapsed\/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 TELLOMAK Trial<\/b><\/a><br \/>Abstract: 466<br \/>\n<br \/>Presentation Type: Oral Presentation<br \/>\n<br \/>Session Name: 625. T Cell, NK Cell, or NK\/T Cell Lymphomas: Clinical and Epidemiological: When Old Meets New in T Cell Lymphomas<br \/>\n<br \/>Presentation Date and Time: Sunday, Dec. 8, 2024, 10:15 AM PT<br \/>\n<\/li>\n<li>\n<b><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fash.confex.com%2Fash%2F2024%2Fwebprogram%2FPaper205923.html&amp;esheet=54159774&amp;newsitemid=20241202835786&amp;lan=en-US&amp;anchor=Phase+1%2F2%2C+Open-Label%2C+Multi-Center+Study+Assessing+the+Safety%2C+Tolerability+and+Preliminary+Efficacy+of+CD123+Natural+Killer+Cell+Engager+%28NKCE%29%2C+SAR443579%2C+in+Combination+With+Venetoclax+and+Azacitidine+in+Patients+With+Newly+Diagnosed+Acute+Myeloid+Leukemia+%28AML%29+Who+Are+Ineligible+for+Intensive+Chemotherapy+%28Sanofi%29&amp;index=3&amp;md5=5e12c166be7306fecfdf00d48e6958a7\" rel=\"nofollow\" shape=\"rect\">Phase 1\/2, Open-Label, Multi-Center Study Assessing the Safety, Tolerability and Preliminary Efficacy of CD123 Natural Killer Cell Engager (NKCE), SAR443579, in Combination With Venetoclax and Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy (Sanofi)<\/a><\/b><br \/>Abstract: 2883.3<br \/>\n<br \/>Presentation Type: Poster Presentation<br \/>\n<br \/>Session Name: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II<br \/>\n<br \/>Date and Time: Sunday, Dec. 8, 2024, 6:00 PM \u2013 8:00 PM PT<\/li>\n<\/ul>\n<p>\nMore information can be found on the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fash.confex.com%2Fash%2F2024%2Fwebprogram%2Fstart.html&amp;esheet=54159774&amp;newsitemid=20241202835786&amp;lan=en-US&amp;anchor=ASH+website&amp;index=4&amp;md5=99c81de6be6619bed53cb32505faf552\" rel=\"nofollow\" shape=\"rect\">ASH website<\/a>.<\/p>\n<p>\n<b>About Lacutamab<\/b><\/p>\n<p>\nLacutamab is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and peripheral T cell lymphoma (PTCL). Rare cutaneous lymphomas of T lymphocytes have a poor prognosis with few efficacious and safe therapeutic options at advanced stages.<\/p>\n<p>\nKIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up 90% of patients with certain aggressive CTCL subtypes, in particular, S\u00e9zary syndrome. It is expressed by up to 50% of patients with mycosis fungoides and peripheral T-cell lymphoma (PTCL). It has a restricted expression on normal tissues.<\/p>\n<p>\nLacutamab is granted European Medicines Agency (EMA) PRIME designation and US Food and Drug Administration (FDA) granted Fast Track designation for the treatment of patients with relapsed or refractory S\u00e9zary syndrome who have received at least two prior systemic therapies.<b> <\/b>Lacutamab is granted orphan drug status in the European Union and in the United States for the treatment of CTCL.<\/p>\n<p>\n<b>About the Innate-Sanofi research collaboration and licensing agreements<\/b><\/p>\n<p>\nInnate Pharma has a research collaboration and license agreement with Sanofi to apply Innate\u2019s proprietary technology to the development of innovative multi-specific antibody formats engaging NK cells through the activating receptors NKp46 and CD16 to kill tumor cells.<\/p>\n<p>\nUnder the terms of the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.innate-pharma.com%2Fmedia%2Fall-press-releases%2Fsanofi-and-innate-pharma-collaborate-new-bispecific-nk-cell-engagers-immuno-oncology&amp;esheet=54159774&amp;newsitemid=20241202835786&amp;lan=en-US&amp;anchor=2016+research+collaboration+and+license+agreement&amp;index=5&amp;md5=75e1081df5930a7b6b3dc14b7c8503e5\" rel=\"nofollow\" shape=\"rect\">2016 research collaboration and license agreement<\/a>, Sanofi is responsible for the development, manufacturing and commercialization of products resulting from the research collaboration, which includes SAR443579\/IPH6101 (Trifunctional anti-CD123 NKp46xCD16 NK cell engager) and SAR445514\/IPH6401 (Trifunctional anti-BCMA NKp46xCD16 NK cell engager). As part of the 2016 agreement, Innate Pharma is eligible to up to \u20ac400m in development and commercial milestone payments as well as royalties on net sales.<\/p>\n<p>\n<b>About Innate Pharma<\/b><\/p>\n<p>\nInnate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: monoclonal antibodies, multi-specific NK Cell Engagers via its ANKET<sup>\u00ae<\/sup> (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC).<\/p>\n<p>\nInnate\u2019s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, several ANKET<sup>\u00ae<\/sup> drug candidates to address multiple tumor types as well as IPH4502 a differentiated ADC in development in solid tumors.<\/p>\n<p>\nInnate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.<\/p>\n<p>\nHeadquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.<\/p>\n<p>\nLearn more about Innate Pharma at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innate-pharma.com%2F&amp;esheet=54159774&amp;newsitemid=20241202835786&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=6&amp;md5=f0f6341dae172a0893af4407872da236\" rel=\"nofollow\" shape=\"rect\">www.innate-pharma.com<\/a> and follow us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Finnate-pharma%2F&amp;esheet=54159774&amp;newsitemid=20241202835786&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=c52063d916a38cc46139cd87df07294a\" rel=\"nofollow\" shape=\"rect\">LinkedIn<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FInnatePharma&amp;esheet=54159774&amp;newsitemid=20241202835786&amp;lan=en-US&amp;anchor=X&amp;index=8&amp;md5=936cf2df375426371b9e737ebc234b56\" rel=\"nofollow\" shape=\"rect\">X<\/a>.<\/p>\n<p>\n<b>Information about Innate Pharma shares<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>ISIN code<\/b><br \/><b>Ticker code<\/b><br \/><b>LEI<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nFR0010331421<\/p>\n<p class=\"bwcellpmargin\">\nEuronext: IPH Nasdaq: IPHA<\/p>\n<p class=\"bwcellpmargin\">\n9695002Y8420ZB8HJE29<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>Disclaimer on forward-looking information and risk factors<\/b><\/p>\n<p>\nThis press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cpotential,\u201d \u201cexpect\u201d \u201cshould,\u201d \u201cwill,\u201d or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company\u2019s reliance on third parties to manufacture its product candidates, the Company\u2019s commercialization efforts and the Company\u2019s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company&#8217;s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\u201cFacteurs de Risque&#8221;) section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amf-france.org&amp;esheet=54159774&amp;newsitemid=20241202835786&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.amf-france.org&amp;index=9&amp;md5=687cec785023e40493c073460c6b23a7\" rel=\"nofollow\" shape=\"rect\">http:\/\/www.amf-france.org<\/a> or on Innate Pharma\u2019s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2023, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company\u2019s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.<\/p>\n<p>\nIn light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n<p>\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>For additional information, please contact:<\/b><br \/><b><span class=\"bwuline\">Investors<\/span><\/b><br \/><b>Innate Pharma<\/b><br \/>Henry Wheeler<br \/>\n<br \/>Tel.: +33 (0)4 84 90 32 88<br \/>\n<br \/><a target=\"_blank\" href=\"ma&#105;&#108;&#116;&#111;&#x3a;&#x48;&#x65;&#x6e;&#x72;y&#46;&#119;&#104;&#101;&#101;&#x6c;&#x65;&#x72;&#x40;&#x69;nn&#97;&#116;&#101;&#45;&#x70;&#x68;&#x61;&#x72;&#x6d;a&#46;f&#114;\" rel=\"nofollow\" shape=\"rect\">&#x48;&#x65;&#x6e;&#x72;&#x79;&#x2e;&#x77;&#x68;&#x65;&#x65;&#x6c;&#x65;&#x72;&#x40;&#x69;&#x6e;&#x6e;&#x61;&#x74;&#x65;&#x2d;&#x70;&#104;&#97;&#114;&#109;&#97;&#46;&#102;&#114;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;#ANKET&#8211;Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced that abstracts related to lacutamab health-related quality of life and translational data from the TELLOMAK trial and SAR443579, Sanofi-partnered ANKET\u00ae asset, have been selected for the American Society of hematology (ASH) Annual Meeting. \u201cWe are proud of &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60427","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;#ANKET&#8211;Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced that abstracts related to lacutamab health-related quality of life and translational data from the TELLOMAK trial and SAR443579, Sanofi-partnered ANKET\u00ae asset, have been selected for the American Society of hematology (ASH) Annual Meeting. \u201cWe are proud of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-03T06:05:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20241202835786\/en\/1245155\/22\/INNATEvertnoirDS.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024\",\"datePublished\":\"2024-12-03T06:05:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\\\/\"},\"wordCount\":1247,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241202835786\\\/en\\\/1245155\\\/22\\\/INNATEvertnoirDS.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\\\/\",\"name\":\"Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241202835786\\\/en\\\/1245155\\\/22\\\/INNATEvertnoirDS.jpg\",\"datePublished\":\"2024-12-03T06:05:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241202835786\\\/en\\\/1245155\\\/22\\\/INNATEvertnoirDS.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241202835786\\\/en\\\/1245155\\\/22\\\/INNATEvertnoirDS.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\/","og_locale":"en_US","og_type":"article","og_title":"Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024 - Pharma Trend","og_description":"MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;#ANKET&#8211;Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced that abstracts related to lacutamab health-related quality of life and translational data from the TELLOMAK trial and SAR443579, Sanofi-partnered ANKET\u00ae asset, have been selected for the American Society of hematology (ASH) Annual Meeting. \u201cWe are proud of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\/","og_site_name":"Pharma Trend","article_published_time":"2024-12-03T06:05:06+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20241202835786\/en\/1245155\/22\/INNATEvertnoirDS.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024","datePublished":"2024-12-03T06:05:06+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\/"},"wordCount":1247,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241202835786\/en\/1245155\/22\/INNATEvertnoirDS.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\/","url":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\/","name":"Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241202835786\/en\/1245155\/22\/INNATEvertnoirDS.jpg","datePublished":"2024-12-03T06:05:06+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20241202835786\/en\/1245155\/22\/INNATEvertnoirDS.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20241202835786\/en\/1245155\/22\/INNATEvertnoirDS.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60427"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60427\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60427"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60427"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}